Trinity Biotech plc
TRIBDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 1, 2015 | $0.22 | 2015-06-05 | 2015-06-09 |
| July 1, 2014 | $0.22 | 2014-06-06 | 2014-06-10 |
| July 1, 2013 | $0.20 | 2013-06-06 | 2013-06-10 |
| June 22, 2012 | $0.15 | 2012-06-06 | 2012-06-08 |
| June 23, 2011 | $0.10 | 2011-06-07 | 2011-06-09 |
Dividends Summary
- Consistent Payer: Trinity Biotech plc has rewarded shareholders with 5 dividend payments over the past 4 years.
- Total Returned Value: Investors who held TRIB shares during this period received a total of $0.89 per share in dividend income.
- Latest Payout: The most recent dividend of $0.22/share was paid 4035 days ago, on July 1, 2015.
- Yield & Schedule: TRIB currently pays dividends yearly with an annual yield of 65.57%.
- Dividend Growth: Since 2011, the dividend payout has grown by 120.0%, from $0.10 to $0.22.
- Dividend Reliability: TRIB has maintained or increased its dividend for 5 consecutive payments.
Company News
Trinity Biotech plc received a non-compliance notice from Nasdaq on February 19, 2026, for failing to maintain the minimum market value of publicly held shares (MVPHS) of $15,000,000 required under Nasdaq Listing Rule 5450(b). The company has 180 calendar days until August 18, 2026, to regain compliance or face potential delisting. The ADSs will ...
Trinity Biotech plc received a non-compliance notice from Nasdaq on February 11, 2026, for failing to maintain the minimum bid price of $1.00 per share. The company has 180 calendar days until August 10, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. Management is evaluating option...
Trinity Biotech collaborates with a bioinformatics company to enhance its EpiCapture prostate cancer test, which uses DNA methylation patterns to monitor disease progression non-invasively.
The global biosensors market is expected to grow from USD 30.04 billion in 2024 to USD 68.72 billion by 2034, with a CAGR of 8.64%. North America dominates the market, while Asia-Pacific shows the fastest growth potential, driven by chronic disease management and technological advancements.
Trinity Biotech has appointed Paul Tivnan, a finance and energy sector executive with over 25 years of leadership experience, to its Board of Directors as a Non-Executive Director.
